FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156214772> ?p ?o ?g. }

• W2156214772 endingPage "4304" @default.
• W2156214772 startingPage "4298" @default.
• W2156214772 abstract "PURPOSE: To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in metastatic colorectal cancer. PATIENTS AND METHODS: Patients had progressive stage IV disease after unsuccessful 5-FU and irinotecan chemotherapy. All patients were evaluated for eligibility for a compassionate 5-FU/oxaliplatin protocol. cDNA was derived from paraffin-embedded tumor specimens to determine TS and ERCC1 mRNA expression relative to the internal reference gene beta-actin using fluorescence-based, real-time reverse transcriptase polymerase chain reaction. RESULTS: The median TS gene expression level from 50 metastasized tumors was 3.4 × 10 −3 (minimum expression, 0.18 × 10 −3 ;maximum expression, 11.5 × 10 −3 ), and the median ERCC1 gene expression level was 2.53 × 10 −3 (minimum, 0.0; maximum, 14.61 × 10 −3 ). The gene expression cutoff values for chemotherapy nonresponse were 7.5 × 10 −3 for TS and 4.9 × 10 −3 for ERCC1. The median survival time for patients with TS ≤ 7.5 × 10 −3 (43 of 50 patients) was 10.2 months, compared with 1.5 months for patients with TS greater than 7.5 × 10 −3 (P < .001). Patients with ERCC1 expression ≤ 4.9 × 10 −3 (40 of 50 patients) had a median survival time of 10.2 months, compared with 1.9 months for patients with ERCC1 expression greater than 4.9 × 10 −3 (P < .001). A TS of 7.5 × 10 −3 segregated significantly into response, stable disease, and progression (P = .02), whereas the association between ERCC1 and response did not reach statistical significance (P = .29). CONCLUSION: These data suggest that intratumoral ERCC1 mRNA and TS mRNA expression levels are independent predictive markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU–resistant metastatic colorectal cancer. Precise definition of the best TS cut point will require further analysis in a large, prospective study." @default.
• W2156214772 created "2016-06-24" @default.
• W2156214772 creator A5019569787 @default.
• W2156214772 creator A5024247368 @default.
• W2156214772 creator A5029279649 @default.
• W2156214772 creator A5036626429 @default.
• W2156214772 creator A5040708686 @default.
• W2156214772 creator A5042950644 @default.
• W2156214772 creator A5045441776 @default.
• W2156214772 creator A5051763335 @default.
• W2156214772 creator A5067387322 @default.
• W2156214772 creator A5071711204 @default.
• W2156214772 date "2001-12-01" @default.
• W2156214772 modified "2023-10-17" @default.
• W2156214772 title "<i>ERCC1</i> and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy" @default.
• W2156214772 cites W1570300525 @default.
• W2156214772 cites W1751651908 @default.
• W2156214772 cites W1802949207 @default.
• W2156214772 cites W1963528972 @default.
• W2156214772 cites W1974716126 @default.
• W2156214772 cites W1977918604 @default.
• W2156214772 cites W1978018057 @default.
• W2156214772 cites W1982640212 @default.
• W2156214772 cites W2024792557 @default.
• W2156214772 cites W2032146688 @default.
• W2156214772 cites W2032930680 @default.
• W2156214772 cites W2045714155 @default.
• W2156214772 cites W2085262578 @default.
• W2156214772 cites W2090794531 @default.
• W2156214772 cites W2098645377 @default.
• W2156214772 cites W2120005875 @default.
• W2156214772 cites W2141735368 @default.
• W2156214772 cites W2145684092 @default.
• W2156214772 cites W2164578725 @default.
• W2156214772 cites W2166182249 @default.
• W2156214772 cites W2168942446 @default.
• W2156214772 cites W2173962436 @default.
• W2156214772 cites W2187668060 @default.
• W2156214772 cites W2316666854 @default.
• W2156214772 cites W4232614050 @default.
• W2156214772 doi "https://doi.org/10.1200/jco.2001.19.23.4298" @default.
• W2156214772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11731512" @default.
• W2156214772 hasPublicationYear "2001" @default.
• W2156214772 type Work @default.
• W2156214772 sameAs 2156214772 @default.
• W2156214772 citedByCount "594" @default.
• W2156214772 countsByYear W21562147722012 @default.
• W2156214772 countsByYear W21562147722013 @default.
• W2156214772 countsByYear W21562147722014 @default.
• W2156214772 countsByYear W21562147722015 @default.
• W2156214772 countsByYear W21562147722016 @default.
• W2156214772 countsByYear W21562147722017 @default.
• W2156214772 countsByYear W21562147722018 @default.
• W2156214772 countsByYear W21562147722019 @default.
• W2156214772 countsByYear W21562147722020 @default.
• W2156214772 countsByYear W21562147722021 @default.
• W2156214772 countsByYear W21562147722022 @default.
• W2156214772 countsByYear W21562147722023 @default.
• W2156214772 crossrefType "journal-article" @default.
• W2156214772 hasAuthorship W2156214772A5019569787 @default.
• W2156214772 hasAuthorship W2156214772A5024247368 @default.
• W2156214772 hasAuthorship W2156214772A5029279649 @default.
• W2156214772 hasAuthorship W2156214772A5036626429 @default.
• W2156214772 hasAuthorship W2156214772A5040708686 @default.
• W2156214772 hasAuthorship W2156214772A5042950644 @default.
• W2156214772 hasAuthorship W2156214772A5045441776 @default.
• W2156214772 hasAuthorship W2156214772A5051763335 @default.
• W2156214772 hasAuthorship W2156214772A5067387322 @default.
• W2156214772 hasAuthorship W2156214772A5071711204 @default.
• W2156214772 hasConcept C104317684 @default.
• W2156214772 hasConcept C104451858 @default.
• W2156214772 hasConcept C121608353 @default.
• W2156214772 hasConcept C123321153 @default.
• W2156214772 hasConcept C126322002 @default.
• W2156214772 hasConcept C134935766 @default.
• W2156214772 hasConcept C143998085 @default.
• W2156214772 hasConcept C2776694085 @default.
• W2156214772 hasConcept C2779309665 @default.
• W2156214772 hasConcept C2780259306 @default.
• W2156214772 hasConcept C2780456651 @default.
• W2156214772 hasConcept C2780962732 @default.
• W2156214772 hasConcept C526805850 @default.
• W2156214772 hasConcept C55493867 @default.
• W2156214772 hasConcept C71924100 @default.
• W2156214772 hasConcept C86803240 @default.
• W2156214772 hasConcept C90924648 @default.
• W2156214772 hasConceptScore W2156214772C104317684 @default.
• W2156214772 hasConceptScore W2156214772C104451858 @default.
• W2156214772 hasConceptScore W2156214772C121608353 @default.
• W2156214772 hasConceptScore W2156214772C123321153 @default.
• W2156214772 hasConceptScore W2156214772C126322002 @default.
• W2156214772 hasConceptScore W2156214772C134935766 @default.
• W2156214772 hasConceptScore W2156214772C143998085 @default.
• W2156214772 hasConceptScore W2156214772C2776694085 @default.
• W2156214772 hasConceptScore W2156214772C2779309665 @default.
• W2156214772 hasConceptScore W2156214772C2780259306 @default.
• W2156214772 hasConceptScore W2156214772C2780456651 @default.
• W2156214772 hasConceptScore W2156214772C2780962732 @default.

• next